DS. Hà Phương Thảo

Khoa Dược- Bệnh viện Giao thông vận tải

, pp.

2. Zahedi Bialvaei A. Rahbar M., et al. (2017), "Linezolid: a promising option in the treatment of Gram-positives", J Antimicrob Chemother, 72(2), pp. 354-364.

3. Bi R. Qin T., et al. (2012), "The emerging problem of linezolid-resistant enterococci", J Glob Antimicrob Resist, 13, pp. 11-19.

4. Dobbs T. E. Patel M., et al. (2006), "Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center", J Clin Microbiol, 44(9), pp. 3368-3370.

5.  Douros Antonios Grabowski Katja, et al. (2015), "Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones", Expert opinion on drug metabolism & toxicology, 11(12), pp. 1849-1859.

6. Ford C. W. Hamel J. C., et al. (1997), "Oxazolidinones: new antibacterial agents", Trends Microbiol, 5(5), pp. 196-200.

7. Fung Horatio B Kirschenbaum Harold L, et al. (2001), "Linezolid: an oxazolidinone antimicrobial agent", Clinical therapeutics, 23(3), pp. 356-391.

8. Gemmell C. G. Ford C. W. (2002), "Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid", J Antimicrob Chemother, 50(5), pp. 665-672.

9. M. Livermore D. (2003), "Linezolid in vitro: mechanism and antibacterial spectrum", J Antimicrob Chemother, 51(2), pp. 9-16.

10. Meka V. G. Gold H. S. (2004), "Antimicrobial resistance to linezolid", Clin Infect Dis, 39(7), pp. 1010-1015.

11. Mendes R. E. Deshpande L. M., et al. (2014), "Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms", Drug Resist Updates, 17(1-2), pp. 1-12.

12. Morales G. Picazo J. J., et al. (2010), "Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus", Clin Infect Dis, 50(6), pp. 821-825.

13. Rao G. G. Konicki R., et al. (2020), "Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics", Ther Drug Monit, 42(1), pp. 83-92.

14. Stevens D. L. Dotter B., et al. (2004), "A review of linezolid: the first oxazolidinone antibiotic", Expert Rev Anti Infect Ther, 2(1), pp.

15. Testing European Committee on Antimicrobial Susceptibility (2022), "Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, valid from 2022-01-01", ., pp.

16. Weinstein Melvin P. II James S. Lewis, et al. (2021), M100 – Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition, pp.

17. Zurenko Gary E Ford Charles W, et al. (1997), "Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid", Expert opinion on investigational drugs, 6(2), pp. 151-158.

18. Bộ Y tế (2021), "Quyết định 2760/QĐ-BYT ban hành ngày 03/06/2021 về việc ban hành “Cập nhật hướng dẫn điều trị lao kháng thuốc”", pp.

19. Bộ Y tế (2020), "Quyết định 1314/QĐ-BYT ban hành ngày 24/03/2020 về việc ban hành “Hướng dẫn chẩn đoán, điều trị và dự phòng bệnh lao”", pp.